Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells 4,471 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 4,471 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the transaction, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at $141,615.05. This represents a 29.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV traded up $0.82 during trading hours on Wednesday, hitting $14.10. 1,928,887 shares of the company’s stock traded hands, compared to its average volume of 933,997. The firm has a market cap of $712.70 million, a P/E ratio of -3.58 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $17.28. The stock’s fifty day moving average price is $12.03 and its two-hundred day moving average price is $12.86.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million. On average, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on KALV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Citizens Jmp cut their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Finally, JMP Securities raised their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $26.63.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in KalVista Pharmaceuticals by 5.1% in the 1st quarter. Bank of New York Mellon Corp now owns 103,530 shares of the specialty pharmaceutical company’s stock worth $1,195,000 after purchasing an additional 4,983 shares during the last quarter. CWM LLC raised its position in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,549 shares during the period. Earned Wealth Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter worth $44,000. Vanguard Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock worth $26,526,000 after buying an additional 43,355 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of KalVista Pharmaceuticals by 12.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 113,124 shares of the specialty pharmaceutical company’s stock worth $1,305,000 after buying an additional 12,776 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).